Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease (CROSBI ID 201309)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Anghel, Rodica ; Bachamann, Alexander ; Beksac, Meral ; Brodowicz, Thomas ; Finek, Jindrich ; Komadina, Radko ; Krzemieniecki, Krzysztof ; Lang, Istvan ; Marencak, Jozef ; Von Moos, Roger et al. Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease // Wiener klinische Wochenschrift, 125 (2013), 15/16; 439-447. doi: 10.1007/s00508-013-0385-4

Podaci o odgovornosti

Anghel, Rodica ; Bachamann, Alexander ; Beksac, Meral ; Brodowicz, Thomas ; Finek, Jindrich ; Komadina, Radko ; Krzemieniecki, Krzysztof ; Lang, Istvan ; Marencak, Jozef ; Von Moos, Roger ; Pechersttorfer, Martin ; Rordorf, Tamara ; Vrbanec, Damir ; Zielinski, Christoph

engleski

Expert opinion 2011 on the use of new- antiresorptive agents in the prevention of skeletal-related events in metastatic bone disease

Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.

anti-resorptive agents; breast cancer; bone metastases

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

125 (15/16)

2013.

439-447

objavljeno

0043-5325

10.1007/s00508-013-0385-4

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost